- Home
- RENB vs VRCA Comparison
RENB vs VRCA Comparison
Compare RENB & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- VRCA
- Stock Information
- Founded
- RENB 2011
- VRCA 2013
- Country
- RENB United States
- VRCA United States
- Employees
- RENB N/A
- VRCA N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- RENB Health Care
- VRCA Health Care
- Exchange
- RENB Nasdaq
- VRCA Nasdaq
- Market Cap
- RENB 57.7M
- VRCA 58.7M
- IPO Year
- RENB N/A
- VRCA 2018
- Fundamental
- Price
- RENB $0.26
- VRCA $5.66
- Analyst Decision
- RENB
- VRCA Hold
- Analyst Count
- RENB 0
- VRCA 5
- Target Price
- RENB N/A
- VRCA $60.00
- AVG Volume (30 Days)
- RENB 866.4K
- VRCA 46.2K
- Earning Date
- RENB 10-09-2025
- VRCA 08-12-2025
- Dividend Yield
- RENB N/A
- VRCA N/A
- EPS Growth
- RENB N/A
- VRCA N/A
- EPS
- RENB N/A
- VRCA N/A
- Revenue
- RENB N/A
- VRCA $14,704,000.00
- Revenue This Year
- RENB N/A
- VRCA $264.34
- Revenue Next Year
- RENB N/A
- VRCA $33.95
- P/E Ratio
- RENB N/A
- VRCA N/A
- Revenue Growth
- RENB N/A
- VRCA 5.72
- 52 Week Low
- RENB $0.22
- VRCA $3.82
- 52 Week High
- RENB $2.10
- VRCA $25.80
- Technical
- Relative Strength Index (RSI)
- RENB 51.07
- VRCA 42.35
- Support Level
- RENB $0.22
- VRCA $5.40
- Resistance Level
- RENB $0.25
- VRCA $6.50
- Average True Range (ATR)
- RENB 0.02
- VRCA 0.58
- MACD
- RENB 0.00
- VRCA -0.02
- Stochastic Oscillator
- RENB 84.44
- VRCA 13.00
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.